KRAS and hepatocellular carcinoma: Since KRAS inhibition does not affect migration in HCC [9], these data point to potential additional functions of PDE6D (e.g., on migration) beyond its effects on KRAS trafficking in HCC, which could be mediated by the potential novel nuclear PDE6D interactors/effectors identified herein.